Download PDF
Semin Liver Dis 2004; 24(4): 335-347
DOI: 10.1055/s-2004-860863
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Gut Peptides and Other Regulators in Obesity

Matthew T. Scharf1 , Rexford S. Ahima1 , 2
  • 1University of Pennsylvania School of Medicine, Division of Endocrinology, Diabetes and Metabolism; and the Neuroscience Graduate Group, Philadelphia, Pennsylvania
  • 2Assistant Professor of Medicine; Director of the Weight Management & Metabolism Program, Presbyterian Medical Center, Philadelphia, Pennsylvania
Further Information

Publication History

Publication Date:
16 December 2004 (online)

    Permissions and Reprints

ABSTRACT

Obesity has reached epidemic levels in industrialized countries and is increasing worldwide. This trend has serious public health consequences, since obesity increases the risk of diabetes, hypertension, heart disease, sleep apnea, cancer, arthritis, cholelithiasis, fatty liver disease, and other complications. Obesity is the result of an imbalance between energy intake and expenditure; hence, an understanding of how gastrointestinal function is integrated with the hormonal regulation of energy balance is pertinent to the pathophysiology of obesity. Nutrients, peptides, and neural afferents from the gut influence the size and frequency of meals and satiety. The long-term regulation of energy stores is mediated primarily through the actions of adiposity hormones, such as leptin and insulin, in the hypothalamus and other neuronal circuits in the brain. Efforts are underway to determine how these peripheral and central pathways may be targeted for treatment of obesity and related diseases.

KEYWORDS

Gastrointestinal system - peptides - nutrients - obesity - adipose tissue - leptin - adiponectin - cytokines

REFERENCES

  • 1 Hedley A A, Ogden C L, Johnson C L, Carroll M D, Curtin L R, Flegal K M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.  JAMA. 2004;  291 2847-2850
    CrossrefPubMedGoogle Scholar
  • 2 Ogden C L, Flegal K M, Carroll M D, Johnson C L. Prevalence and trends in overweight among US children and adolescents, 1999-2000.  JAMA. 2002;  288 1728-1732
    CrossrefPubMedGoogle Scholar
  • 3 Kopelman P G. Obesity as a medical problem.  Nature. 2000;  404 635-643
    CrossrefPubMedGoogle Scholar
  • 4 Calle E E, Thun M J, Petrelli J M, Rodriguez C, Heath Jr C W. Body-mass index and mortality in a prospective cohort of U. S. adults.  N Engl J Med. 1999;  341 1097-1105
    CrossrefPubMedGoogle Scholar
  • 5 Ahima R S, Flier J S. Adipose tissue as an endocrine organ.  Trends Endocrinol Metab. 2000;  11 327-332
    PubMedGoogle Scholar
  • 6 Unger R H. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome.  Endocrinology. 2003;  144 5159-5165
    CrossrefPubMedGoogle Scholar
  • 7 Barsh G S, Farooqi I S, O'Rahilly S. Genetics of body-weight regulation.  Nature. 2000;  404 644-651
    PubMedGoogle Scholar
  • 8 Zimmet P, Alberti K G, Shaw J. Global and societal implications of the diabetes epidemic.  Nature. 2001;  414 782-787
    CrossrefPubMedGoogle Scholar
  • 9 Kennedy G C. The role of depot fat in the hypothalamic control of food intake in the rat.  Proc R Soc Lond B Biol Sci. 1953;  140 578-596
    PubMedGoogle Scholar
  • 10 Harris R B, Martin R J. Specific depletion of body fat in parabiotic partners of tube-fed obese rats.  Am J Physiol. 1984;  247 R380-R386
    PubMedGoogle Scholar
  • 11 Hervey G R. The effects of lesions in the hypothalamus in parabiotic rats.  J Physiol. 1959;  145 336-352
    PubMedGoogle Scholar
  • 12 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372 425-432 , Erratum in: Nature. 1995;  374 479
    CrossrefPubMedGoogle Scholar
  • 13 Chen H, Charlat O, Tartaglia L A et al.. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice.  Cell. 1996;  84 491-495
    CrossrefPubMedGoogle Scholar
  • 14 Flier J S. Obesity wars: molecular progress confronts an expanding epidemic.  Cell. 2004;  116 337-350
    CrossrefPubMedGoogle Scholar
  • 15 Elmquist J K, Elias C F, Saper C B. From lesions to leptin: hypothalamic control of food intake and body weight.  Neuron. 1999;  22 221-232
    CrossrefPubMedGoogle Scholar
  • 16 Ahima R S, Osei S Y. Molecular regulation of eating behavior: new insights and prospects for therapeutic strategies.  Trends Mol Med. 2001;  7 205-213
    CrossrefPubMedGoogle Scholar
  • 17 Mayer J. Glucostatic mechanism of regulation of food intake.  N Engl J Med. 1953;  249 13-16
    CrossrefPubMedGoogle Scholar
  • 18 Thompson D A, Campbell R G. Hunger in humans induced by 2-deoxy-D-glucose: glucoprivic control of taste preference and food intake.  Science. 1977;  198 1065-1068
    PubMedGoogle Scholar
  • 19 Oomura Y, Ono T, Ooyama H, Wayner M J. Glucose and osmosensitive neurones of the rat hypothalamus.  Nature. 1969;  222 282-284
    CrossrefPubMedGoogle Scholar
  • 20 Bergen H T, Monkman N, Mobbs C V. Injection with gold thioglucose impairs sensitivity to glucose: evidence that glucose-responsive neurons are important for long-term regulation of body weight.  Brain Res. 1996;  734 332-336
    CrossrefPubMedGoogle Scholar
  • 21 Novin D, VanderWeele D A, Rezek M. Infusion of 2-deoxy-D-glucose into the hepatic-portal system causes eating: evidence for peripheral glucoreceptors.  Science. 1973;  181 858-860
    PubMedGoogle Scholar
  • 22 Bray G A. Amino acids, protein, and body weight.  Obes Res. 1997;  5 373-376
    PubMedGoogle Scholar
  • 23 Fernstrom J D, Wurtman R J. Brain serotonin content: physiological dependence on plasma tryptophan levels.  Science. 1971;  173 149-152
    Google Scholar
  • 24 Kasser T R, Harris R B, Martin R J. Level of satiety: fatty acid and glucose metabolism in three brain sites associated with feeding.  Am J Physiol. 1985;  248 R447-R452
    PubMedGoogle Scholar
  • 25 Sergeyev V, Broberger C, Gorbatyuk O, Hokfelt T. Effect of 2-mercaptoacetate and 2-deoxy-D-glucose administration on the expression of NPY, AGRP, POMC, MCH and hypocretin/orexin in the rat hypothalamus.  Neuroreport. 2000;  11 117-121
    PubMedGoogle Scholar
  • 26 Friedman M I, Harris R B, Ji H, Ramirez I, Tordoff M G. Fatty acid oxidation affects food intake by altering hepatic energy status.  Am J Physiol. 1999;  276 R1046-R1053
    PubMedGoogle Scholar
  • 27 Nagase H, Bray G A, York D A. Effects of pyruvate and lactate on food intake in rat strains sensitive and resistant to dietary obesity.  Physiol Behav. 1996;  59 555-560
    CrossrefPubMedGoogle Scholar
  • 28 Tso P, Liu M, Kalogeris T J. The role of apolipoprotein A-IV in food intake regulation.  J Nutr. 1999;  129 150-156
    PubMedGoogle Scholar
  • 29 Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor.  Trends Endocrinol Metab. 2001;  12 118-122
    PubMedGoogle Scholar
  • 30 Tschop M, Smiley D L, Heiman M L. Ghrelin induces adiposity in rodents.  Nature. 2000;  407 908-913
    CrossrefPubMedGoogle Scholar
  • 31 Cummings D E, Weigle D S, Frayo R S et al.. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.  N Engl J Med. 2002;  346 1623-1630
    CrossrefPubMedGoogle Scholar
  • 32 Holdstock C, Engstrom B E, Ohrvall M, Lind L, Sundbom M, Karlsson F A. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans.  J Clin Endocrinol Metab. 2003;  88 3177-3183
    CrossrefPubMedGoogle Scholar
  • 33 Cowley M A, Smith R G, Diano S et al.. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.  Neuron. 2003;  37 649-661
    CrossrefPubMedGoogle Scholar
  • 34 Chen H Y, Trumbauer M E, Chen A S et al.. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein.  Endocrinology. 2004;  145 2607-2612
    CrossrefPubMedGoogle Scholar
  • 35 Sun Y, Ahmed S, Smith R G. Deletion of ghrelin impairs neither growth nor appetite.  Mol Cell Biol. 2003;  23 7973-7981
    CrossrefPubMedGoogle Scholar
  • 36 Sun Y, Wang P, Zheng H, Smith R G. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor.  Proc Natl Acad Sci USA. 2004;  101 4679-4684
    CrossrefPubMedGoogle Scholar
  • 37 Smith G P, Gibbs J. Satiating effect of cholecystokinin.  Ann N Y Acad Sci. 1994;  713 236-241
    PubMedGoogle Scholar
  • 38 Moran T H, Katz L F, Plata-Salaman C R, Schwartz G J. Disordered food intake and obesity in rats lacking cholecystokinin A receptors.  Am J Physiol. 1998;  274 R618-R625
    PubMedGoogle Scholar
  • 39 Kopin A S, Mathes W F, McBride E W et al.. The cholecystokinin-A receptor mediates inhibition of food intake yet is not essential for the maintenance of body weight.  J Clin Invest. 1999;  103 383-391 , Erratum in: J Clin Invest 1999;103:759
    PubMedGoogle Scholar
  • 40 Berglund M M, Hipskind P A, Gehlert D R. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes [review].  Exp Biol Med (Maywood). 2003;  228 217-244
    PubMedGoogle Scholar
  • 41 Batterham R L, Cowley M A, Small C J et al.. Gut hormone PYY(3-36) physiologically inhibits food intake.  Nature. 2002;  418 650-654
    CrossrefPubMedGoogle Scholar
  • 42 Batterham R L, Cohen M A, Ellis S M et al.. Inhibition of food intake in obese subjects by peptide YY3-36.  N Engl J Med. 2003;  349 941-948
    CrossrefPubMedGoogle Scholar
  • 43 Tschop M, Castaneda T R, Joost H G et al.. Physiology: does gut hormone PYY3-36 decrease food intake in rodents?.  Nature. 2004;  430 165-167 , Erratum in Nature. 2004;  431 1038 , Withcomb, DC [corrected to Whitcomb, DC]
    CrossrefPubMedGoogle Scholar
  • 44 Clark J T, Sahu A, Kalra P S, Balasubramaniam A, Kalra S P. Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY.  Regul Pept. 1987;  17 31-39
    CrossrefPubMedGoogle Scholar
  • 45 Stanley B G, Daniel D R, Chin A S, Leibowitz S F. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion.  Peptides. 1985;  6 1205-1211
    CrossrefPubMedGoogle Scholar
  • 46 Kanatani A, Mashiko S, Murai N et al.. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice.  Endocrinology. 2000;  141 1011-1016
    CrossrefPubMedGoogle Scholar
  • 47 Jia B Q, Taylor I L. Failure of pancreatic polypeptide release in congenitally obese mice.  Gastroenterology. 1984;  87 338-343
    PubMedGoogle Scholar
  • 48 Asakawa A, Inui A, Yuzuriha H et al.. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance.  Gastroenterology. 2003;  124 1325-1336
    CrossrefPubMedGoogle Scholar
  • 49 Ueno N, Inui A, Iwamoto M et al.. Decreased food intake and body weight in pancreatic polypeptide-overexpressing mice.  Gastroenterology. 1999;  117 1427-1432
    PubMedGoogle Scholar
  • 50 Batterham R L, Le Roux C W, Cohen M A et al.. Pancreatic polypeptide reduces appetite and food intake in humans.  J Clin Endocrinol Metab. 2003;  88 3989-3992
    CrossrefPubMedGoogle Scholar
  • 51 Berntson G G, Zipf W B, O'Dorisio T M, Hoffman J A, Chance R E. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome.  Peptides. 1993;  14 497-503
    CrossrefPubMedGoogle Scholar
  • 52 Holst J J. Glucagon-like Peptide 1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential.  Trends Endocrinol Metab. 1999;  10 229-235
    PubMedGoogle Scholar
  • 53 Verdich C, Flint A, Gutzwiller J P et al.. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans.  J Clin Endocrinol Metab. 2001;  86 4382-4389
    CrossrefPubMedGoogle Scholar
  • 54 Nauck M A, Kleine N, Orskov C, Holst J J, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients.  Diabetologia. 1993;  36 741-744
    CrossrefPubMedGoogle Scholar
  • 55 Turton M D, O'Shea D, Gunn I et al.. A role for glucagon-like peptide-1 in the central regulation of feeding.  Nature. 1996;  379 69-72
    CrossrefPubMedGoogle Scholar
  • 56 Drucker D J, Lovshin J, Baggio L et al.. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.  Ann N Y Acad Sci. 2000;  921 226-232
    PubMedGoogle Scholar
  • 57 Scrocchi L A, Hill M E, Saleh J, Perkins B, Drucker D J. Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.  Diabetes. 2000;  49 1552-1560
    PubMedGoogle Scholar
  • 58 Tang-Christensen M, Larsen P J, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.  Nat Med. 2000;  6 802-807
    CrossrefPubMedGoogle Scholar
  • 59 Dakin C L, Gunn I, Small C J et al.. Oxyntomodulin inhibits food intake in the rat.  Endocrinology. 2001;  142 4244-4250
    CrossrefPubMedGoogle Scholar
  • 60 Baggio L L, Huang Q, Brown T J, Drucker D J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.  Gastroenterology. 2004;  127 546-558
    CrossrefPubMedGoogle Scholar
  • 61 Cohen M A, Ellis S M, Le Roux C W et al.. Oxyntomodulin suppresses appetite and reduces food intake in humans.  J Clin Endocrinol Metab. 2003;  88 4696-4701
    CrossrefPubMedGoogle Scholar
  • 62 Meier J J, Nauck M A, Schmidt W E, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited.  Regul Pept. 2002;  107 1-13
    CrossrefPubMedGoogle Scholar
  • 63 Gault V A, Flatt P R, O'Harte F P. Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.  Biochem Biophys Res Commun. 2003;  308 207-213
    CrossrefPubMedGoogle Scholar
  • 64 Gault V A, O'Harte F P, Flatt P R. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?.  Neuropeptides. 2003;  37 253-263
    CrossrefPubMedGoogle Scholar
  • 65 Miyawaki K, Yamada Y, Ban N et al.. Inhibition of gastric inhibitory polypeptide signaling prevents obesity.  Nat Med. 2002;  8 738-742
    CrossrefPubMedGoogle Scholar
  • 66 Yamada K, Wada E, Santo-Yamada Y, Wada K. Bombesin and its family of peptides: prospects for the treatment of obesity.  Eur J Pharmacol. 2002;  440 281-290
    CrossrefPubMedGoogle Scholar
  • 67 Gutzwiller J P, Drewe J, Hildebrand P, Rossi L, Lauper J Z, Beglinger C. Effect of intravenous human gastrin-releasing peptide on food intake in humans.  Gastroenterology. 1994;  106 1168-1173
    PubMedGoogle Scholar
  • 68 Ohki-Hamazaki H, Watase K, Yamamoto K et al.. Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity.  Nature. 1997;  390 165-169
    CrossrefPubMedGoogle Scholar
  • 69 Hoppener J W, Ahren B, Lips C J. Islet amyloid and type 2 diabetes mellitus.  N Engl J Med. 2000;  343 411-419
    CrossrefPubMedGoogle Scholar
  • 70 Reda T K, Geliebter A, Pi-Sunyer F X. Amylin, food intake, and obesity.  Obes Res. 2002;  10 1087-1091
    CrossrefPubMedGoogle Scholar
  • 71 Erlanson-Albertsson C, York D. Enterostatin-a peptide regulating fat intake.  Obes Res. 1997;  5 360-372
    PubMedGoogle Scholar
  • 72 Lin L, York D A. Amygdala enterostatin induces c-Fos expression in regions of hypothalamus that innervate the PVN.  Brain Res. 2004;  1020 147-153
    CrossrefPubMedGoogle Scholar
  • 73 Ahima R S, Flier J S. Leptin.  Annu Rev Physiol. 2000;  62 413-437
    CrossrefPubMedGoogle Scholar
  • 74 Coleman D L. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice.  Diabetologia. 1978;  14 141-148
    PubMedGoogle Scholar
  • 75 Flier J S. Clinical review 94: What's in a name? In search of leptin's physiologic role.  J Clin Endocrinol Metab. 1998;  83 1407-1413
    CrossrefPubMedGoogle Scholar
  • 76 Erickson J C, Hollopeter G, Palmiter R D. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y.  Science. 1996;  274 1704-1707
    CrossrefPubMedGoogle Scholar
  • 77 Segal-Lieberman G, Bradley R L, Kokkotou E et al.. Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype.  Proc Natl Acad Sci U S A. 2003;  100 10085-10090
    CrossrefPubMedGoogle Scholar
  • 78 Ahima R, Osei S Y. Leptin and appetite control in lipodystrophy.  J Clin Endocrinol Metab. 2004;  89 4254-4257
    CrossrefPubMedGoogle Scholar
  • 79 Howard J K, Cave B J, Oksanen L J, Tzameli I, Bjorback C, Flier J S. Enhanced leptin sensitivity and attenuation of diet-induced obesity in mice with haploinsufficiency of Socs3.  Nat Med. 2004;  10 734-738
    PubMedGoogle Scholar
  • 80 Mori H, Hanada R, Hanada T et al.. Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity.  Nat Med. 2004;  10 739-743
    PubMedGoogle Scholar
  • 81 Zabolotny J M, Bence-Hanulec K K, Stricker-Krongrad A et al.. PTP1B regulates leptin signal transduction in vivo.  Dev Cell. 2002;  2 489-495
    CrossrefPubMedGoogle Scholar
  • 82 Cheng A, Uetani N, Simoncic P D et al.. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B.  Dev Cell. 2002;  2 497-503
    CrossrefPubMedGoogle Scholar
  • 83 Schwartz M W, Figlewicz D P, Baskin D G, Woods S C, Porte Jr D. Insulin in the brain: a hormonal regulator of energy balance.  Endocr Rev. 1992;  13 387-414
    CrossrefPubMedGoogle Scholar
  • 84 Benoit S C, Air E L, Coolen L M et al.. The catabolic action of insulin in the brain is mediated by melanocortins.  J Neurosci. 2002;  22 9048-9052
    PubMedGoogle Scholar
  • 85 Bruning J C, Gautam D, Burks D J et al.. Role of brain insulin receptor in control of body weight and reproduction.  Science. 2000;  289 2122-2125
    Google Scholar
  • 86 Niswender K D, Morrison C D, Clegg D J et al.. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: a key mediator of insulin-induced anorexia.  Diabetes. 2003;  52 227-231
    PubMedGoogle Scholar
  • 87 Niswender K D, Schwartz M W. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities.  Front Neuroendocrinol. 2003;  24 1-10
    CrossrefPubMedGoogle Scholar
  • 88 Berg A H, Combs T P, Scherer P E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism.  Trends Endocrinol Metab. 2002;  13 84-89
    CrossrefPubMedGoogle Scholar
  • 89 Maeda N, Shimomura I, Kishida K et al.. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30.  Nat Med. 2002;  8 731-737
    CrossrefPubMedGoogle Scholar
  • 90 Kubota N, Terauchi Y, Yamauchi T et al.. Disruption of adiponectin causes insulin resistance and neointimal formation.  J Biol Chem. 2002;  277 25863-25866
    CrossrefPubMedGoogle Scholar
  • 91 Yamauchi T, Kamon J, Minokoshi Y et al.. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.  Nat Med. 2002;  8 1288-1295
    CrossrefPubMedGoogle Scholar
  • 92 Goldstein B J, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function.  J Clin Endocrinol Metab. 2004;  89 2563-2568
    CrossrefPubMedGoogle Scholar
  • 93 Yamauchi T, Kamon J, Ito Y et al.. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects.  Nature. 2003;  423 762-769
    CrossrefPubMedGoogle Scholar
  • 94 Hug C, Wang J, Ahmad N S, Gogan J S, Tsao T S, Lodish H F. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin.  Proc Natl Acad Sci U S A. 2004;  101 10308-10313
    CrossrefPubMedGoogle Scholar
  • 95 Steppan C M, Lazar M A. The current biology of resistin.  J Intern Med. 2004;  255 439-447
    CrossrefPubMedGoogle Scholar
  • 96 Rajala M W, Qi Y, Patel H R et al.. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting.  Diabetes. 2004;  53 1671-1679
    CrossrefPubMedGoogle Scholar
  • 97 Steppan C M, Bailey S T, Bhat S et al.. The hormone resistin links obesity to diabetes.  Nature. 2001;  409 307-312
    CrossrefPubMedGoogle Scholar
  • 98 Rajala M W, Obici S, Scherer P E, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production.  J Clin Invest. 2003;  111 225-230
    CrossrefPubMedGoogle Scholar
  • 99 Banerjee R R, Rangwala S M, Shapiro J S et al.. Regulation of fasted blood glucose by resistin.  Science. 2004;  303 1195-1198
    CrossrefPubMedGoogle Scholar
  • 100 Wellen K E, Hotamisligil G S. Obesity-induced inflammatory changes in adipose tissue.  J Clin Invest. 2003;  112 1785-1788
    CrossrefPubMedGoogle Scholar
  • 101 Moller D E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes.  Trends Endocrinol Metab. 2000;  11 212-217
    PubMedGoogle Scholar
  • 102 Wallenius V, Wallenius K, Ahren B et al.. Interleukin-6-deficient mice develop mature-onset obesity.  Nat Med. 2002;  8 75-79
    CrossrefPubMedGoogle Scholar

Rexford S AhimaM.D. Ph.D. 

University of Pennsylvania School of Medicine, Division of Endocrinology, Diabetes and Metabolism

764 Clinical Research Building, 415 Curie Blvd

Philadelphia, PA 19104

Email: ahima@mail.med.upenn.edu

      >